[ Price : $8.95]
FDA issues Nephron Pharmaceuticals the first Warning Letter citing a prescription drug manufacturer for promoting its product for ...[ Price : $8.95]
A new CDER investigation of real-world evidence confirms that patients taking levothyroxine benefit equally from generic and brand...[ Price : $8.95]
Federal Register notice: FDA makes available a final guidance entitled Opioid Use Disorder: Endpoints for Demonstrating Effectiven...[ Price : $8.95]
Federal Register notice: FDA seeks comments on an information collection revision for Orphan Drugs; 21 CFR Part 316.[ Price : $8.95]
FDA classifies as Class 1 a recall of Becton Dickinsons Alaris Pump Module and Pump Module Door Assembly Replacement Kits because ...[ Price : $8.95]
Federal Register notice: FDA makes available a draft guidance entitled Bladder Cancer: Developing Drugs and Biologics for Adjuvant...[ Price : $8.95]
FDA updates its information Web page about eligibility for its Voluntary Malfunction Summary Reporting program.[ Price : $8.95]
FDA issues Mesoblast a complete response letter on its BLA for remestemcel-L for treating pediatric steroid-refractory acute graft...